Literature DB >> 7357340

Role of pituitary hormones in regulating renal vitamin D metabolism in man.

D J Brown, E Spanos, I MacIntyre.   

Abstract

Studies in animals and tissue culture have shown the importance of prolactin and growth hormone in regulating renal 1 alpha-hydroxylase activity and plasma concentrations of 1,25-dihydroxycholecalciferol (1,25(OH)2D3). Evidence for a similar role for these hormones in man was sought by using a radioreceptor assay to measure plasma 1,25(OH)2D3 concentrations in 20 normal subjects, 12 patients receiving dialysis, 11 patients with primary hyperparathyroidism, 10 pregnant women, seven women with prolactinoma, and 14 patients with acromegaly. Circulating 1,25(OH)2D3 concentrations were appreciably raised in the patients with primary hyperparathyroidism and the pregnant women (P less than 0.001), slightly but significantly increased in the patients with prolactinoma (P less than 0.05), and greatly raised in those with acromegaly (P less than 0.001). These results suggest that prolactin and growth hormone are important regulators of renal vitamin D metabolism in the physiological conditions of pregnancy, lactation, and growth in man.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7357340      PMCID: PMC1600180          DOI: 10.1136/bmj.280.6210.277

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  11 in total

1.  A sensitive, precise, and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma.

Authors:  J A Eisman; A J Hamstra; B E Kream; H F DeLuca
Journal:  Arch Biochem Biophys       Date:  1976-09       Impact factor: 4.013

2.  The action and control of the calcium-regulating hormones.

Authors:  I MacIntyre
Journal:  J Endocrinol Invest       Date:  1978-07       Impact factor: 4.256

3.  Circulating 1alpha,25-dihydroxyvitamin D in the chicken: enhancement by injection of prolactin and during egg laying.

Authors:  E Spanos; J W Pike; M R Haussler; K W Colston; I M Evans; A M Goldner; T A McCain; I MacIntyre
Journal:  Life Sci       Date:  1976-12-01       Impact factor: 5.037

4.  Vitamin D metabolism: physiological regulation in egg-laying Japanese quail.

Authors:  A D Kenny
Journal:  Am J Physiol       Date:  1976-06

5.  Filter assay for 1alpha, 25-dihydroxyvitamin D3. Utilization of the hormone's target tissue chromatin receptor.

Authors:  P F Brumbaugh; D H Haussler; K M Bursac; M R Haussler
Journal:  Biochemistry       Date:  1974-09-24       Impact factor: 3.162

6.  Regulation of vitamin-D metabolism without parathyroid hormone.

Authors:  R G Larkins; K W Colston; L S Galante; S J MacAuley; I M Evans; I MacIntyre
Journal:  Lancet       Date:  1973-08-11       Impact factor: 79.321

7.  Separation of hydroxylated derivatives of vitamin D3 by high speed liquid chromatography (HSLC).

Authors:  E W Matthews; P G Byfield; K W Colston; I M Evans; L S Galante; I Macintyre
Journal:  FEBS Lett       Date:  1974-11-01       Impact factor: 4.124

8.  Physiologic hyperparathyroidism in pregnancy.

Authors:  W G Cushard; M A Creditor; J M Canterbury; E Reiss
Journal:  J Clin Endocrinol Metab       Date:  1972-05       Impact factor: 5.958

9.  Calcium metabolism in normal human pregnancy.

Authors:  R P Heaney; T G Skillman
Journal:  J Clin Endocrinol Metab       Date:  1971-10       Impact factor: 5.958

10.  Elevated 1,25-dihydroxyvitamin D plasma levels in normal human pregnancy and lactation.

Authors:  R Kumar; W R Cohen; P Silva; F H Epstein
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

View more
  10 in total

Review 1.  Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature.

Authors:  Reshma Shah; Angelo Licata; Nelson M Oyesiku; Adriana G Ioachimescu
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

2.  Reversal of severe osteopenia in a patient with hyperprolactinemia treated with bromocriptine.

Authors:  J S Lindberg; F O Kolb; R A Blau; M R Powell
Journal:  West J Med       Date:  1988-09

3.  Bone mineral homeostasis, bone growth, and mineralisation during years of pubertal growth: a unifying concept.

Authors:  S Krabbe; I Transbøl; C Christiansen
Journal:  Arch Dis Child       Date:  1982-05       Impact factor: 3.791

4.  Characterization of vitamin D metabolism in active acromegaly in the setting of bolus (150,000 IU) cholecalciferol treatment.

Authors:  Alexandra A Povaliaeva; Viktor P Bogdanov; Artem Yu Zhukov; Ekaterina A Pigarova; Larisa K Dzeranova; Liudmila Ya Rozhinskaya; Galina A Mel'nichenko; Natalia G Mokrysheva
Journal:  Endocrine       Date:  2022-02-09       Impact factor: 3.633

5.  Free 1,25-dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and subjects with liver disease.

Authors:  D D Bikle; E Gee; B Halloran; J G Haddad
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

Review 6.  The effects of hyperprolactinemia on bone and fat.

Authors:  Amal Shibli-Rahhal; Janet Schlechte
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

7.  Interrelations of calcium-regulating hormones during normal pregnancy.

Authors:  M Whitehead; G Lane; O Young; S Campbell; G Abeyasekera; C J Hillyard; I MacIntyre; K G Phang; J C Stevenson
Journal:  Br Med J (Clin Res Ed)       Date:  1981-07-04

8.  Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia.

Authors:  M P Caraceni; E Corghi; S Ortolani; S Casazza; A D'Alberton; T Motta
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

9.  Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration.

Authors:  R Bouillon; F A Van Assche; H Van Baelen; W Heyns; P De Moor
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

10.  Patients with Active Acromegaly are at High Risk of 25(OH)D Deficiency.

Authors:  Jowita Halupczok-Żyła; Aleksandra Jawiarczyk-Przybyłowska; Marek Bolanowski
Journal:  Front Endocrinol (Lausanne)       Date:  2015-06-02       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.